What is claimed is:

1. Use of an immunoconjugate for the manufacture of a medicament for treating a disease associated with target cells expressing CD138 in a patient,

wherein the immunoconjugate comprises at least one targeting antibody targeting CD138 expressing cells, and at least one effector molecule,

wherein said targeting antibody is functionally attached to said effector molecule to form said immunoconjugate,

wherein the targeting antibody comprises a light chain with at least 70% sequence identity with SEQ ID NO:2 and a heavy chain with at least 70% sequence identity with SEQ ID NO:1,

wherein the medicament is to be administered to the patient in an amount of the immunoconjugate that is an effective amount, and wherein the effective amount is a tolerable amount,

and wherein the disease is relapsed or refractory multiple myeloma.

2. Use according to claim 1 wherein the patient is being treated with at least one cytotoxic agent.

3. Use of at least one immunoconjugate for the manufacture of a medicament for treating a proliferative disease associated with target cells expressing CD138 in a patient with a refractory disease phenotype,

wherein the at least one immunoconjugate comprises a targeting antibody targeting CD138 expressing cells and at least one effector molecule,

wherein said targeting antibody is functionally attached to said effector molecule to form said immunoconjugate,

wherein the targeting antibody comprises a light chain with at least 70% sequence identity with SEQ ID NO:2 and a heavy chain with at least 70% sequence identity with SEQ ID NO:1,

wherein the medicament is to be administered to the patient in combination with at least one cytotoxic agent.

4. Use according to claim 2 or claim 3 wherein the at least one cytotoxic agent is a proteasome inhibitor, an immunomodulatory or an anti-angiogenic agent, a DNA alkylating agent or a mixture of two or more thereof.

5. Use according to claim 4, wherein the at least one cytotoxic agent is bortezomib, thalidomide, pomalidomide, lenalidomide, melphalan or a mixture of two or more thereof.

6. Use according to any one of claims 1 to 3 wherein said immunoconjugate comprises nBT062 or a targeting antibody having at least 80%, 85%, 90%, 95%, 98%, 99% sequence identity with nBT062 or wherein said immunoconjugate corresponds to BT062.

7. Use according to any one of claims 1 to 4 wherein the medicament is to be administered to the patient in an amount of the immunoconjugate from 5 mg/m^2 to 200 mg/m^2 or a pharmacokinetic equivalent of 5 mg/m^2 to 200 mg/m^2 .